Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Expectations By $0.49 EPS

Halozyme Therapeutics (NASDAQ:HALO) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49, FiscalAI reports. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the business posted $1.54 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics updated its FY 2026 guidance to 8.650-9.000 EPS.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Record second-quarter performance: Total revenue rose 48% year over year to $481 million, while royalty revenue increased 50% to $307.7 million. Adjusted EBITDA reached $328.8 million and non-GAAP EPS was $2.28.
• 2026 guidance was raised: Halozyme now expects total revenue of $1.835 billion-$1.91 billion, royalty revenue of $1.22 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.28 billion, and non-GAAP EPS of $8.65-$9.00.
• ENHANZE product diversification accelerated: Royalties from newer launches—including OCREVUS ZUNOVO, Opdivo Qvantig, and RYBREVANT SC—increased approximately 80% sequentially, complementing continued growth from DARZALEX SC, VYVGART Hytrulo, and PHESGO.
• Strong partnership momentum expanded the long-term pipeline: Halozyme signed five collaboration and licensing agreements across the quarter and July, including deals with GSK, Incyte, Vertex, and Oruka, generating $35.5 million in upfront revenue and expanding ENHANZE into ADCs and nucleic-acid therapies.
• Litigation remains an important uncertainty: Halozyme is pursuing injunctions against Merck in roughly eight countries and plans to appeal four U.S. patent-review decisions, although management expressed strong confidence it will ultimately prevail.

Halozyme Therapeutics Trading Up 2.6%

NASDAQ HALO traded up $2.17 on Thursday, hitting $85.76. 2,679,037 shares of the company were exchanged, compared to its average volume of 1,643,316. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $86.00. The firm has a market capitalization of $10.17 billion, a P/E ratio of 30.85, a price-to-earnings-growth ratio of 0.35 and a beta of 0.85. The company’s 50 day moving average price is $75.74 and its 200-day moving average price is $71.25.

Insider Activity

In related news, CEO Helen Torley sold 1,923 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,477 shares of company stock worth $5,102,643 over the last 90 days. 2.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC grew its stake in Halozyme Therapeutics by 1,552.5% during the 4th quarter. Corient Private Wealth LLC now owns 196,329 shares of the biopharmaceutical company’s stock valued at $13,213,000 after acquiring an additional 184,448 shares in the last quarter. Caitlin John LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth approximately $465,000. First Citizens Bank & Trust Co. boosted its holdings in shares of Halozyme Therapeutics by 2.8% during the fourth quarter. First Citizens Bank & Trust Co. now owns 8,913 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 242 shares during the period. State of Tennessee Department of Treasury boosted its holdings in shares of Halozyme Therapeutics by 38.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 57,516 shares of the biopharmaceutical company’s stock worth $4,124,000 after purchasing an additional 16,105 shares during the period. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $592,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q2 results significantly exceeded expectations: Revenue rose 48% year over year to $481 million, versus the $402.28 million analyst consensus, while adjusted EPS of $2.28 surpassed estimates of $1.79 and increased from $1.54 a year earlier. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Royalty growth underscores the strength of Halozyme’s platform: Royalty revenue increased 50% year over year to $308 million. Management highlighted the repeatability, scalability, diversification and durability of the ENHANZE drug-delivery platform. Halozyme Q2 2026 Earnings Call Transcript
• Positive Sentiment: Full-year 2026 guidance was raised: Halozyme now expects revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP EPS of $8.65 to $9.00. The EPS outlook is above the approximately $8.02 consensus estimate. Halozyme 2026 Guidance Update
• Positive Sentiment: Business development momentum improved: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year target of three. The agreements potentially broaden future revenue and royalty opportunities. Halozyme Collaboration Agreements
• Neutral Sentiment: The strong results raise expectations for continued execution; investors will likely focus on whether new collaborations translate into durable commercial royalties and whether Halozyme can sustain its elevated growth rates.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HALO shares. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.